Peptide Comparison
Thymagen vs Cardiogen
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Thymagen and Cardiogen share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: limited western evidence. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| Thymagen | Cardiogen | |
|---|---|---|
| Class | Khavinson short peptide bioregulator | Khavinson short peptide bioregulator |
| Drug class | Immune | Tissue Repair |
| Mechanism | Thymic gene expression modulation | Tissue-specific gene expression modulation in cardiomyocytes |
| Route | Oral / Intranasal | Oral |
| Half-life | Short (minutes) | Short (minutes) |
| Dosage (research) | Oral capsule 1-2x daily | Oral capsule 1-2x daily |
| Evidence tier | Russian Research | Russian Research |
| Research depth | 1 indexed | 11 indexed |
| Availability | Research | Research |
| Reported risks | Limited Western evidence | Limited Western evidence; no regulatory approval |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Thymagen or Cardiogen?
Thymagen and Cardiogen share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
What is the difference between Thymagen and Cardiogen?
Thymagen is classed as Khavinson short peptide bioregulator; Cardiogen is classed as Khavinson short peptide bioregulator. Reported mechanism: Thymagen, Thymic gene expression modulation; Cardiogen, Tissue-specific gene expression modulation in cardiomyocytes. Reported half-life: Thymagen, Short (minutes); Cardiogen, Short (minutes). Routes in published studies: Thymagen, Oral / Intranasal; Cardiogen, Oral.
Which has stronger evidence, Thymagen or Cardiogen?
Thymagen and Cardiogen sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Thymagen is graded Russian Research, with 2 cited sources on its reference page and 1 indexed studies. Cardiogen is graded Russian Research, with 2 cited sources on its reference page and 11 indexed studies.
Which is more accessible, Thymagen or Cardiogen?
Neither Thymagen nor Cardiogen is an FDA-approved drug. Catalog status: Thymagen, Research; Cardiogen, Research.
Are Thymagen and Cardiogen ever combined?
Thymagen and Cardiogen appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…